Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347473 | 1.00 | ADORA2A (0.62) | ADORA2AADORA2BADORA3 | |
| SCHEMBL20271368 | 0.96 | ADORA2A (0.61) | ADORA2AADORA2BADORA3 | |
| SCHEMBL1138979 | 0.88 | ADORA2A (0.60) | ADORA2AADORA2BADORA3 | |
| SCHEMBL25307074 | 0.88 | LMNA (0.59) | ADORA2AADORA2BADORA3 | |
| SCHEMBL27803476 | 0.88 | CYP2C19 (0.53) | ADORA2AADORA2BADORA3 | |
| SCHEMBL6826553 | 0.87 | LMNA (0.58) | ADORA2AADORA2BADORA3 | |
| SCHEMBL28343811 | 0.85 | LMNA (0.55) | ADORA2AADORA2BADORA3 | |
| SCHEMBL5347799 | 0.84 | ADORA2A (0.60) | ADORA2AADORA2BADORA3 | |
| SCHEMBL5347819 | 0.84 | ADORA2A (0.60) | ADORA2AADORA2BADORA3 | |
| SCHEMBL5356824 | 0.84 | ADORA2A (0.60) | ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682903-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10655127-B2 | RNA amidates and thioamidates for RNAi | GERON CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3342425-B1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORP (US) | 2019-12-18 | — | — | EP | disclosed |
| US-10196641-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3342425-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180119147-A1 | Rna Amidates and Thioamidates for Rnai | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-1667522-B1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORP (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9822360-B2 | RNA amidates and thioamidates for RNAi | GERON CORPORATION (US) | 2017-11-21 | — | — | US | disclosed |
| US-9657296-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170130225-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-7494982-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070275919-A1 | Rna Amidates and Thioamidates for Rnai | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2007-11-29 | — | — | US | disclosed |
| EP-1694842-A1 | RNA AMIDATES AND THIOAMIDATES FOR RNAI | Geron Corporation (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1667522-A2 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | Geron Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050113325-A1 | Modified oligonucleotides for telomerase inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2005-05-26 | — | — | US | disclosed |
| WO-2005047506-A1 | RNA AMIDATES AND THIOAMIDATES FOR RNAI | GERON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005023994-A2 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-0882061-A4 | SUGAR-MODIFIED GAPPED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2000-12-13 | — | — | EP | disclosed |
| EP-0882061-A1 | SUGAR-MODIFIED GAPPED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997030067-A1 | SUGAR-MODIFIED GAPPED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10655127-B2 | RNA amidates and thioamidates for RNAi | NSUN3, RNGTT, RNMT | ADORA2A 2465/4885ADORA2B 2094/4885ADORA3 1018/4885 |
| US-20070275919-A1 | Rna Amidates and Thioamidates for Rnai | NSUN3, RNGTT, RNMT | ADORA2A 2465/4885ADORA2B 2094/4885ADORA3 1018/4885 |
| US-20050113325-A1 | Modified oligonucleotides for telomerase inhibition | TERT, TRDMT1, TERF2 | ADORA2A 2642/4885ADORA2B 2768/4885ADORA3 2803/4885 |
| US-20180119147-A1 | Rna Amidates and Thioamidates for Rnai | NSUN3, RNGTT, RNMT | ADORA2A 2465/4885ADORA2B 2094/4885ADORA3 1018/4885 |
| US-10196641-B2 | Modified oligonucleotides for telomerase inhibition | TERT, TRDMT1, TERF2 | ADORA2A 2642/4885ADORA2B 2768/4885ADORA3 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.